Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Chronic Neutrophilic Leukemia

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Leukemia (1924)

Acute Myelogenous Leukemia (892)

Acute Lymphocytic Leukemia (385)

Chronic Lymphocytic Leukemia (293)

Chronic Myeloid Leukemia (271)

B Acute Lymphoblastic Leukemia (163)

T Acute Lymphoblastic Leukemia (38)

Childhood B Acute Lymphoblastic Leukemia (37)

Chronic Myelomonocytic Leukemia (18)

Hairy Cell Leukemia (18)

Prolymphocytic Leukemia (14)

Acute Promyelocytic Leukemia (12)

Chronic Eosinophilic Leukemia (4)

Juvenile Myelomonocytic Leukemia (4)

Leukemia (1924)

Acute Myelogenous Leukemia (892)

Acute Lymphocytic Leukemia (385)

Chronic Lymphocytic Leukemia (293)

Chronic Myeloid Leukemia (271)

B Acute Lymphoblastic Leukemia (163)

T Acute Lymphoblastic Leukemia (38)

Childhood B Acute Lymphoblastic Leukemia (37)

Chronic Myelomonocytic Leukemia (18)

Hairy Cell Leukemia (18)

Prolymphocytic Leukemia (14)

Acute Promyelocytic Leukemia (12)

Chronic Eosinophilic Leukemia (4)

Juvenile Myelomonocytic Leukemia (4)

›

CSF3R T618I	Chronic Neutrophilic Leukemia	CSF3R T618I	Chronic Neutrophilic Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
CSF3R S783	Chronic Neutrophilic Leukemia	CSF3R S783	Chronic Neutrophilic Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D
CSF3R T618I	Chronic Neutrophilic Leukemia	CSF3R T618I	Chronic Neutrophilic Leukemia	dasatinib Resistant: D – Preclinical dasatinib Resistant : D	dasatinib Resistant: D – Preclinical dasatinib Resistant : D